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Abstract
AIM: To assess the efficacy of triple therapy (peginte-
rferon or high dose standard interferon, plus ribavirin 
and amantadine) in nonresponders to prior combination 
therapy.
METHODS: A total of 196 patients were enrolled in a 
multicenter, open, randomized study. Patients were given 
180 μg/wk of peginterferon-alpha-2a (40 kDa) plus 
ribavirin (800-1000 mg/d) and amantadine (200 mg/d) 
for 48 wk (group A) or interferon-alpha-2a (6 MU/d for 
4 wk, 3 MU/d for 20 wk, and 3 MU tiw for 24 wk) plus 
ribavirin (800-1000 mg/d) and amantadine (200 mg/d) 
for 48 wk (group B). 
RESULTS: Overall sustained virologic response (SVR) 
was 26.6% (32.1% and 19.5% in group A and B, P  = 
0.057). Baseline ALT >120 UI/L (OR 2.4; 95% CI:1.11 
to 5.20; P  = 0.026) and HCV RNA negativity after 
12 wk (OR 8.7; 95% CI: 3.87 to 19.74; P  < 0.0001) 
were independently associated with SVR. Therapy 
discontinuation occurred less frequently in patients 
treated with peginterferon than standard interferon (P  = 
0.036).
CONCLUSION: More than 25% of nonresponders to 
combination therapy can eradicate HCV infection when 
retreated with triple therapy, especially if they have 
a high baseline ALT and are treated with pegylated 
interferon.
© 2006 The WJG Press. All rights reserved.
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INTRODUCTION
While advances in the treatment of  HCV chronic hepatitis 
have markedly improved outcomes for treatment-naïve 
patients, a large number of  patients still fail to eradicate 
HCV infection[1-4], and improving the re-treatment success 
rates of  these nonresponsive patients remains a key 
challenge in hepatitis care[5-7]. It has been reported that 
12%-20% of  patients who did not respond to standard 
interferon (IFN) monotherapy can achieve a sustained 
response when retreated with high doses of  interferon plus 
ribavirin (RBV)[8-12]. However, the most effective treatment 
strategies for patients who fail to respond to combination 
therapy have yet to be established, and results for re-
treatment with pegylated interferon and ribavirin in these 
patients are generally more variable and less positive[13-17]. 
The results can also be difficult to interpret since most 
of  the available data derive from studies that included 
both relapsers and nonresponders to different therapeutic 
schedules. However, considering the high number of  
patients who do not respond to combination therapy, the 
need for new antiviral re-treatment regimens becomes 
evident.
    It has recently been suggested that the addition of  
amantadine (AMA) to interferon and ribavirin (triple 
therapy) may improve the therapeutic efficacy of  com-
bination therapy, possibly by potentiating the antiviral 
activity through interleukin production[18]. Amantadine has 
an intrinsic antiviral activity against influenza A virus by 
blocking its cellular internalization and possibly interferes 
with the replication of  other viruses including HCV[19-21]. 
Results on the use of  triple therapy in patients with HCV 
chronic hepatitis are conflicting. A recent meta-analysis[22] 
reported that triple therapy was of  no advantage com-
pared to standard combination therapy in treatment-naive 
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patients or in relapsed patients[23,24], whereas it markedly 
improved the sustained virologic response in nonrespond-
ers to interferon monotherapy[25-27]. The efficacy of  triple 
therapy in nonresponders to combination therapy has pri-
marily been investigated in only a small series of  patients, 
making it difficult to draw defined conclusions from these 
data on the use of  triple therapy in such patients[28-32]. A re-
cent study in a larger patient population of  nonresponders 
(n = 200) found a higher sustained virological response in 
patients receiving triple therapy (24%) vs combined therapy 
(16%), although the difference was not statistically signifi-
cant[33].
    The aims of  this multicenter, randomized study car-
ried out in a well-selected series of  patients nonresponsive 
to combination therapy were (1) to define the rate of  
sustained virological response in patients previously non-
responsive to combination therapy, when retreated with 
triple therapy (consisting of  recombinant interferon or 
peginterferon (PegIFN) plus ribavirin and amantadine); 
(2) to assess whether PegIFN is superior to a high daily 
dose of  IFN when used in a triple therapy regimen; and (3) 
to compare the tolerability, side effects and adherence to 
therapy in patients treated with the two different schedules.
MATERIALS AND METHODS
From February 2001 to June 2002, 196 patients aged 
between 18 and 65 years were included in this multicenter 
cooperative study. All patients had to be nonresponders to 
interferon plus ribavirin given for at least 24 wk. Patients 
who had previously been treated with interferon alone or 
who had received combination therapy for a shorter period 
were excluded from the study. Patients were recruited 
by 21 Liver Centers operating in 21 General Hospitals 
sited in Lombardy (North of  Italy) and belonging to the 
Gruppo Epatologico Lombardo (GEL). A noncompetitive 
recruitment was employed and each center had to enroll 
at least 5 patients. The failure to respond to previous 
combinat ion therapy was def ined as absence of  
normalization of  transaminases and/or detectable serum 
HCV RNA level after 24 wk of  therapy. A washout period 
of  at least 6 mo from the end of  therapy to inclusion in 
this study was required. For inclusion, patients had to 
fulfill the following criteria: (1) persistent transaminase 
elevation throughout the previous 6 mo; (2) a liver biopsy 
taken within the past 18 mo showing histological findings 
compatible with chronic hepatitis or cirrhosis; (3) serum 
HCV RNA positive by quantitative polymerase chain 
reaction (PCR) test (second-generation Amplicor HCV, 
Roche Diagnostic System, Basel, Switzerland). Patients 
were excluded from the study if  one of  the following 
criteria were present: (1) decompensated cirrhosis; (2) 
co-infection with human immunodeficiency virus; (3) 
positivity for HBsAg; (4) autoimmune hepatitis; (5) alcohol 
abuse (daily alcohol intake > 60 g in males and > 40 g in 
females); (6) haemoglobin concentration less than 120 
g/L in women and 130 g/L in men; (7) white cell count 
less than 3 × 109/L, platelet count below 100 × 109/L; 
(8) moderate/severe depression or other psychiatric 
diseases; (9) seizure disorders; (10) cardiovascular, 
respiratory or renal clinically manifested diseases; (11) 
hemoglobinopathies; (12) poorly controlled diabetes 
mellitus; (13) immunologically mediated disease; (14) 
ultrasonographic evidence of  focal liver lesions. 
Study design
This was a multicenter, open-label, randomized, parallel-
group study. Randomization was centralized and patients 
were stratified by HCV genotype (genotype 1 vs other 
genotypes).
    Patients were randomized to receive peginterferon-α-
2a (Pegasys; Roche, Basel, Switzerland) at the dose of  180 
mcg once a wk for 48 wk (Treatment A) or interferon 
alfa-2a (Roferon; Roche) at the dose of  6 MU/d for 4 
wk followed by 3 MU/d for the next 20 wk and 3 MU 
tiw until the end of  the study (wk 48) (Treatment B). 
Both groups received ribavirin (Copegus, Roche, Basel, 
Switzerland) at the dose of  800 mg (for patients weighing 
less than 75 kg) or 1000 mg (for patients weighing 75 
kg or more) and amantadine (Mantadan; Boehringer 
Ingelheim, Florence, Italy) at a total daily dose of  200 mg. 
The treatment period lasted 48 wk, with a 24-wk follow-
up period. Sustained virological response was defined as 
persistent negative HCV RNA at 6 mo after completion 
of  therapy. Patients were considered nonresponders and 
therapy was stopped if  HCV-RNA was still positive at 24 
wk of  therapy.
    Basal laboratory assessment consisted of  liver function 
tests, hematologic tests, renal function tests, autoantibodies 
(ANA, AMA, ASMA, antiLKM), alphafetoprotein, 
serum iron, transferrin and ferritin, HBsAg, anti-HBc. 
Quantitative HCV RNA was measured by standardized 
PCR assay with a lower limit of  detection of  less than 
1 × 106 copies/L (second-generation Amplicor HCV 
Monitor, Roche), qualitative HCV RNA was measured by 
a standardized PCR assay with a lower limit of  detection 
of  0.1 × 103 copies/L (second-generation Amplicor HCV, 
Roche Diagnostic System). Determination of  infecting 
HCV genotype was performed in serum samples prior to 
therapy using Innolipa, Genetics Technique (Innogenetics, 
Belgium/Bayer Diagnostics, USA).
    Patients were clinically evaluated at regular intervals: 15, 
30, 45 and 60 d after the first dose of  treatment and every 
month thereafter until the end of  the study. Biochemical 
tests were performed at 15 and 30 d and at monthly 
intervals until the end of  treatment and every 3 mo during 
follow-up. During treatment, HCV-RNA was assayed 
after 12, 24, 36, and 48 wk of  therapy and after 12 and 24 
wk from the end of  the treatment. At 12 and 72 wk, the 
serum HCV RNA level was assayed by qualitative analysis.
Histology
Liver biopsies were formalin fixed, embedded in paraffin 
and stained by hematoxylin-eosin, reticulin and Masson’s 
trichrome method. Histologic diagnosis was made by one 
independent pathologist and classified according to the 
internationally accepted criteria as chronic hepatitis (mild, 
moderate or severe) or cirrhosis. Inflammatory activity 
(grading) and fibrosis (staging) were semi-quantified using 
the Ishak scoring system[34]. Local institutional committees 
of  participating hospitals approved the study protocol and 
all amendments. All patients provided written informed 
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consent. All the study procedures were in accordance with 
the principles of  the Helsinki Declaration.
Primary and secondary endpoints
Clearance of  HCV RNA at the end of  the 6-mo follow 
up period was the primary end-point. Safety, adherence 
to therapy and therapy interruption were considered as 
secondary end-points.
Safety assessment
Safety was assessed by physical examinations, laboratory 
tests and spontaneous reports of  clinical adverse events. 
According to the study protocol, Peginterferon-α-2a 
dose modification to 135, 90 or 45 mg/wk and ribavirin 
dose reductions were allowed in patients with clinically 
significant adverse events or laboratory abnormalities, 
including hematological toxicity as manifested by the 
hemoglobin level of  less than 100 g/L, white cell count of  
less than 2.5 × 109/L, granulocyte count of  less than 1 × 
109/L, and platelet count of  less than 70 × 109/L. Therapy 
was discontinued in patients with neutrophils below 0.7 
× 109/L, Hb below 85 g/L, and platelets below 50 × 
109/L. Adherence to treatment was considered when drug 
consumption (either pegylated/standard IFN or ribavirin 
or both) was higher than 70% of  the scheduled dose for a 
time period longer than 70% of  the scheduled time. 
Statistical analysis
It was calculated that at least 100 patients per group were 
needed to detect a difference of  20% in the proportion 
of  SVR between treatment A and treatment B with an 
alpha error of  0.05 and study power (beta error) of  0.8. 
Summary statistics (no. of  cases, mean, median, standard 
deviation, minimum and maximum) were calculated for 
continuous variables, and the number and percentage of  
patients in each category were provided for categorical 
data. The treatment comparison of  interest was the 
recombinant interferon-α-2a plus ribavirin plus amantadine 
against peginterferon-α-2a plus ribavirin plus amantadine. 
Differences between the treatments were assessed by 
the Cochran-Mantel-Haenszel test stratified according to 
HCV genotype (HCV genotype 1 vs other genotypes). The 
relationship between patients’ baseline characteristics and 
SVR was examined by logistic regression analyses. Univariate 
logistic regressions were used to confirm the importance 
of  previously identified prognostic factors. To assess the 
independence of  these factors, a backward elimination 
procedure was then undertaken using the factors that were 
significant in the univariate analyses. A log-linear model 
was used to investigate the interactions between HCV-
RNA eradication after 12 wk of  therapy and the variables 
predictive of  sustained virologic response. All P values 
reported are two-sided.
    All patients who received at least one dose of  study 
medication were included in all efficacy analyses, and if  
they had undergone at least one safety assessment after 
baseline, they were included in the safety analysis. Patients 
with missing data in the primary or secondary efficacy 
endpoints were considered as nonresponders.
RESULTS
Two hundred thirty two consecutive nonresponder patients 
to combination therapy were considered eligible for this 
study. Thirty six patients were not randomized because of  
refusal of  therapy (23 cases) or inability to attend a regular 
follow up (13 cases). One hundred six patients were 
randomized to receive peginterferon-α-2a plus ribavirin 
and amantadine and 90 to receive interferon α-2a plus 
ribavirin and amantadine. Eight patients randomized to 
treatment B refused to take the study drugs and were not 
further evaluated (Figure 1). The characteristics of  patients 
at baseline are shown in Table 1. None of  the variables 
considered was statistically significantly different between 
the two groups.
    A SVR of  26.6% was obtained in the overall series 
of  patients. However, when the two treatments were 
compared, a better but not significant SVR was achieved 
in patients receiving PegIFN than in those receiving high 
doses (daily doses for 6 mo) of  standard interferon (32.1% 
vs 19.5%, P = 0.057). The better response in patients 
treated with PegIFN was present at all on-treatment time 
intervals (Figure 2). The rate of  sustained response in the 
30 patients with cirrhosis was 30% with no difference 
between patients treated with PegIFN or standard IFN. 
    Univariate analysis performed on non-missing data, 
considering the overall series of  patients, showed that 
genotype non 1, higher grade score and baseline ALT were 
significantly associated with sustained virologic response 
(Table 2). Patients younger than 40 years had a significantly 
better response when treated with PegIFN than standard 
IFN (48% vs 11%, P = 0.017). Also patients with fibrosis 
less than 3 and those with viremia higher than 2 million 
Table 1  Baseline characteristics of patients (Information are 
not available for all patients) n  (%)
Characteristic     All    PegIFN +RBV + AMA
(n  = 188)     (n  = 106)
IFN+RBV+AMA 
(n  = 82)
Male/Female 146/42 79/27 67/15
Age
   ≤ 40 yr   42 (22) 23 (22) 19 (23)
   > 40 yr 146 (78) 83 (78) 63 (77)
BMI
   ≤ 25 kg/m2 107 (64) 60 (65) 47 (63)
   > 25 kg/m2   61 (36) 33 (35) 28 (37)
ALT
   ≤ 120 UI/L 107 (62) 64 (65) 43 (58)
   > 120 UI/L  66 (38) 35 (35) 31 (42)
HCV genotype 
   1 147 (78) 82 (77) 65 (79)
   2 21 (11) 12 (11) 9 (11)
   3 8 (4) 7 (7) 1 (1)
   4 12 (6) 5  (5) 7  (9)
HCV RNA
   ≤ 2 x 106 copies/mL 74 (73) 41 (76) 33 (69)
   > 2 x 106 copies/mL  28 (27) 13 (24) 15 (31)
Stage
   ≤ 3 127 (69) 71 (70) 56 (68)
   > 3 56 (31) 30 (30) 26 (32)
Grade
   ≤ 10 167 (92) 94 (91) 73 (92)
   > 10 15 (8) 9 (9) 6 (8)
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copies had a significantly better response when treated 
with PegIFN than standard IFN (respectively 38% vs 18%, 
P = 0.018 and 46% vs 7%, P = 0.029) (Table 3). 
    The chance of  achieving a sustained response was 
significantly higher in patients who were HCV RNA 
negative as compared to those who were HCV RNA 
positive at 12 wk of  therapy (39/78, 50% vs 11/110 10%, 
P < 0.0001). 
    To examine the influence of  potentially important 
prognostic factors on SVR, factors known to affect 
response (HCV genotype, age, BMI, stage and grade, ALT 
value, previous IFN total dose taken, biochemical and 
virologic response after 12 wk of  treatment) were first 
examined individually by univariate logistic regression 
analysis for each factor for all treatment groups combined. 
ALT (< 120 UI/L vs > 120 UI/L), the biochemical and 
the virologic response at wk 12 were associated with SVR (P 
< 0.10). These predictive factors were entered in the final 
backward regression analysis. Two factors independently 
and significantly increased the odds of  achieving a 
sustained virologic response: a baseline ALT value greater 
than 120 UI/L (odds-ratio 2.40; 95% CI: 1.11 to 5.20; P 
= 0.026), and the virologic response after 12 weeks of  
therapy (odds-ratio 8.75; 95% CI: 3.87 to 19.74; P < 0.0001). 
Logistic regression analysis was used to characterize 
further the relation between SVR, patients’ characteristics 
at baseline, biochemical and virologic response after 12 
wk of  treatment, and the study treatments. In the final 
backward regression analysis were entered the treatment 
given, the ALT value at baseline, the biochemical and the 
virologic response after 12 wk of  treatment. The model 
confirmed that the baseline ALT value greater than 120 
UI/L and the virologic response after 12 wk of  treatment 
were prognostic factors that significantly increased 
the odds of  achieving a sustained virologic response. 
Odds-ratios and their 95% confidence intervals and the 
associated p-values were equal to those obtained in the 
logistic regression model reported above.
    Twenty-seven patients discontinued the study 
treatments: 10 in group A and 17 in group B (9.4% vs 
20.7%, P = 0.036). The reasons for discontinuation are 
reported in Table 4. Dosage reduction, reported in 30 
patients (17 treated with PegIFN and 13 with standard 
IFN), was related to hematological alterations in 12 of  
the patients who received pegylated interferon and in 7 
of  those treated with standard interferon. Dermatological 
manifestations (mainly reported in patients treated with 
pegylated interferon) and cephalea were the causes of  
dosage reduction in the remaining patients. Adherence 
Table 2  Sustained virologic response for all treatment groups 
combined according to the baseline characteristics of patients
Characteristics Sustained virologic response P 1
Genotype 1 32/147 22% 0.0085
         Non 1 18/41 44%
Age  ≤ 40 yr 13/42 31% NS
         > 40 yr 37/146 25%
BMI ≤ 25 kg/m2 32/107 30% NS
         > 25 kg/m2 12/61 20%
Stage ≤ 3 37/127 29% NS
         > 3 12/56 21%
Grade ≤ 10 42/167 25% 0.03
         > 10 8/15 53%
ALT ≤ 120 UI/L 22/107 21% 0.03
         > 120 UI/L 24/66 36%
HCV-RNA ≤ 2 × 106 copies/mL 23/74 31% NS
         > 2 × 106 copies/mL 7/28 25%
Previous Total IFN ≤ 500 MU 20/91 22% NS
         > 500 MU 25/82 30%
1 Fisher's exact test; NS: Not significant.
Assessed for elegibility n  = 232
Excluded n  = 36
-Refused to participate = 23
-Unable to attend regular 
  follow  up = 13
Randomized n  = 196
Allocated to intervention B n  = 90
-Received = 82
-Did not receive = 8
Reason = refused to participate
Allocated to intervention A 
n  = 106
-Received = 106
-Did not receive = 0
Lost to follow up = 0
Discontinued intervention = 10
Lost to follow up = 0
Discontinued intervention = 17
Analysed = 106 Analysed = 82
Figure 1  Progress of patients through the trial showing details of patients’ 
recruitment, enrollment, randomization and therapy withdrawal until completion of 
the study. 
Figure 2  Comparison of virologic responses over time in patients treated 
with peginterferon plus ribavirin and amantadine (Group A), and with standard 
interferon plus ribavirin and amantadine (Group B). Percentages of patients 
negative for HCV-RNA during and after therapy with peginterferon plus ribavirin 
and amantadine (black bar) or standard interferon plus ribavirin and amantadine 
(white bar) are shown. Significance between the two treatments is shown at each 
time interval.
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lower than 70% in the first 24 wk of  therapy was observed 
in 8/106 (7.5%) patients in treatment A and in 8/82 (10%) 
in treatment B. No significant difference in the rate of  
response was observed between patients who did or did 
not reduce therapy.
DISCUSSION
This is the first randomized study to compare the efficacy 
of  two triple therapy regimens-recombinant interferon 
α-2a either standard or pegylated, in combination with 
ribavirin and amantadine-in a well-selected series of  
patients nonresponsive to previous treatment with 
interferon and ribavirin. Our data demonstrate that after 
12 mo of  treatment, a sustained virologic response is 
obtained in a surprisingly high number of  these difficult-
to-treat patients. Better results in terms of  sustained 
response (32% vs 19% of  SVR) were observed in patients 
treated by pegylated interferon than in those treated by a 
high daily dose of  standard interferon. Baseline elevated 
ALT level and undetectable serum HCV RNA at wk 12 
of  therapy were the independent predictors of  sustained 
response, irrespective of  the interferon used (pegylated 
interferon or high dose standard interferon). As a whole, 
triple therapy was well tolerated and safe, with a higher 
frequency of  therapy discontinuation in patients treated 
by standard interferon than in those treated by pegylated 
interferon.
    The overall rate of  SVR observed in the present study 
of  nonresponders to combination therapy (standard 
interferon plus ribavirin), most of  whom had been 
already submitted to several treatments, is higher than that 
generally observed in previously reported studies. The 
results are even more impressive when considering patients 
treated by pegylated interferon. In particular, patients with 
high viral load seemed to respond better when treated with 
pegylated interferon, even if  the small number of  cases in 
which basal viral load was available does not allow definite 
conclusions to be drawn. Only a few studies have been 
carried out to assess the efficacy of  retreatment in patients 
nonresponsive to combination therapy and most of  them 
included small series of  patients and did not disaggregate 
relapsers from true nonresponders[24,25,27]. Schiffmann et al[14] 
reported an overall SVR rate of  18% after retreatment for 
48 wk with PegIFN plus RBV, and even lower rates were 
observed in patients with unfavourable predictors such as 
genotype 1 and/or high viral load. Teuber et al[28] reported 
a 22% SVR in previous nonresponders either to interferon 
or combination therapy when retreated with triple therapy 
including amantadine, however, the SVR rate dropped 
down to 12% in those patients who had previously been 
given two or more courses of  antiviral treatment. Typically, 
SVR rates in nonresponders to combination therapy 
retreated with triple therapy have averaged approximately 
12%[29-32], although in a recent placebo-controlled study the 
SVR with amantadine triple therapy was 24%[33], while in a 
small group of  genotype 1, nonresponsive patients without 
cirrhosis, a SVR of  42% was reported[35]. 
    We cannot exclude that a selection bias may partially 
explain the high rate of  response found in our study. 
Although the main clinical and virologic characteristics (age, 
prevalence of  genotype 1) of  our patients are those usually 
observed in nonresponders to combination therapy, in 
our series the prevalence of  cirrhosis was only 16% and 
the majority of  patients had a fibrosis stage lower than 3 
according to the Ishak score, differing from Schiffman’s[14] 
study which included only patients with bridging fibrosis 
or cirrhosis. However, we observed a high SVR (30%) in 
patients with cirrhosis (stage 5 and 6) by the Ishak score 
and no significant difference in sustained response between 
patients with or without cirrhosis. We are therefore more 
prone to think that the higher antiviral efficacy found 
in our study is more likely linked to the addition of  
amantadine to combination therapy. In keeping with our 
results Maynard et al[33] demonstrated that 24% of  non 
responders treated by triple therapy achieved an SVR of  
16% of  those treated by double therapy. The mechanism 
by which amantadine enhances the antiviral effect of  
interferon and ribavirin is unclear and remains largely 
speculative. It is well known that amantadine may act as 
an antiviral drug and its synergistic action in combination 
with IFN and RBV may function through the modulation 
of  the host immune-response[36]. Although the mechanism 
Table 3  Sustained virologic response in patients treated 
with Peg IFN or standard IFN according to the baseline 
characteristics of patients 
Characteristic          PegIFN+RBV+AMA IFN+RBV+AMA P
Genotype 1 21/82 26% 11/65 17% NS
    Non 1 13/24 54% 5/17 29% NS
Age ≤ 40 yr 11/23 48% 2/19 11% 0.017
    > 40 yr 23/83 28% 14/63 22% NS
BMI ≤ 25 kg/m2 22/60 37% 10/47 21% NS
    > 25 kg/m2 8/33 24% 4/28 14% NS
Stage ≤ 3 27/71 38% 10/56 18% 0.018
    > 3 6/30 20% 6/26 23% NS
Grade ≤ 10 28/94 30% 14/73 19% NS
    > 10 6/9 67% 2/6 33% NS
ALT ≤ 120 UI/L 17/64 27% 5/43 12% NS
    > 120 UI/L 15/35 43% 9/31 29% NS
HCV-RNA ≤ 2 × 106 
copies/mL
15/41 37% 8/33 24% NS
   > 2 × 106 copies/mL 6/13 46% 1/15 7% 0.029
Table 4  Reasons for treatment discontinuation
                                     PegIFN +RBV + AMA 
                                             (n  = 106)
IFN+RBV+AMA 
(n  = 82)
Treatment discontinuation for any 10 (9.4%) 17 (20.7%)
Reason1
Study drug noncompliance 2 11
Demyelinizing neuropathy 1
Depression 1 1
Erythema 1
Pulmonary fibrosis 1
Hyperthyroidism 1
Hyperthyroidism & Insomnia 1
Increased ALT 1
Leukopenia 1 3
Dyspnoea, Cough, Pruritus 1
Unknown reason 1
1 Fisher’s exact test:  P = 0.036.
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underlying the potential synergism between these drugs 
is not clear, our results suggest that triple therapy, in 
particular when PegIFN is used, has to be considered as 
a valid option in nonresponders to combination therapy 
since it allows a sustained viral clearance in about one third 
of  otherwise nonresponsive patients. 
    In keeping with the results obtained in treatment-naïve 
patients and in relapsers[1-4], PegIFN achieved a better 
response than standard interferon even though the latter 
was administered at a high daily dosage. Although the 
difference in SVR observed between the two treatment 
groups did not reach a statistical difference (P = 0.057), 
our results strongly suggest that in nonresponders, 
pegylated interferon should represent the first choice 
interferon in retreatment strategies. Our suggestion is 
further strengthened by the evidence of  a lower incidence 
of  therapy discontinuation in patients treated with PegIFN 
than in those treated with high dose standard interferon. 
    Baseline ALT value and undetectable serum HCV RNA 
at wk 12 of  therapy were the variables independently 
associated with sustained response. Unexpectedly, HCV 
genotype did not emerge as an independent predictor 
of  response by univariate analysis. In fact, in the present 
series, although genotype 1 patients responded less well 
than those with other genotypes, the difference did not 
maintain the significance at multivariate analysis. One 
possible explanation of  this discrepancy is that the 
previous treatments may have selected patients in whom 
several and possibly new mechanisms of  therapeutic 
resistance have emerged over time. In the present series 
the SVR in patients with genotype 1 was 22% (26% 
and 17% in those treated with PegIFN or standard 
IFN, respectively), a rate that is markedly higher than 
reported in other studies[14,37]. Interestingly, in treatment-
naïve patients infected with genotype 1 the addition of  
amantadine to interferon therapy also led to an increased 
rate of  SVR[38]. Although the problem remains of  whether 
or not the retreatment of  genotype 1 nonresponders is 
justified in terms of  cost-efficacy[39], at the moment triple 
therapy including amantadine should be regarded as the 
most useful regimen to be proposed for these patients. 
    In the present study the addition of  amantadine did 
not negatively affect the safety profile of  combination 
therapy. In fact, triple therapy was found to be safe and 
well tolerated in the large majority of  patients and the 
frequency and type of  side effects did not differ from 
that observed in other series of  nonresponders treated 
with standard or pegylated interferon plus ribavirin[1,2,40,41]. 
The higher rate of  treatment withdrawal in patients 
treated with high dose standard recombinant interferon 
than in those receiving pegylated interferon parallels the 
results observed in treatment-naïve patients receiving 
pegylated interferon when compared to high dose 
induction therapy[42]. Interestingly, in our study, only two 
patients experienced depression severe enough to require 
treatment discontinuation. It is possible that the addition 
of  amantadine, which is known to possess antidepressant 
properties[43,44], may have decreased the overall incidence 
of  depression, which is often the cause of  premature 
therapy withdrawal. This is another relevant aspect that, in 
association with the low cost of  amantadine, supports the 
use of  triple therapy in nonresponsive patients.
    Although our study was not specifically designed to 
assess the predictive value of  virologic response, some 
information can be drawn. Undetectable serum HCV 
RNA at wk 12 of  therapy was the strongest independent 
predictor of  SVR, in fact 50% of  the patients who 
were HCV-RNA negative after 12 wk of  treatment and 
10% of  those who were still positive, became sustained 
responders. In particular, the predictive negative value 
(90%) observed in our series at week 12 is slightly lower 
than that usually observed in treatment-naïve patients 
receiving combination therapy[45], suggesting that it may be 
more useful to wait until wk 24 before deciding whether 
to withdraw therapy. These findings further confirm that 
in this group of  difficult-to-treat patients the variables and 
prognostic factors usually associated with response cannot 
be employed. 
    In conclusion, the present multicenter randomized study 
demonstrated that triple therapy, in particular employing 
pegylated-α-2a interferon plus ribavirin and amantadine, is 
an effective therapeutic option for patients nonresponsive 
to previous treatment with interferon plus ribavirin and can 
rescue at least one-fourth of  these patients to sustained 
viral clearance. Although many questions remain regarding 
the role of  amantadine in the treatment of  HCV chronic 
hepatitis, these results, taken together with data from 
recent studies, provide encouragement for retreatment of  
nonresponders to combination therapy with triple therapy. 
Although our results need to be confirmed further in 
placebo-controlled studies, they seem to be particularly 
interesting when taking into account that addition of  
amantadine is low cost and safe and could offer hope to 
patients for whom no alternative therapies are available. 
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